Short-term application of topical corticosteroids can help acute psoriasis patientsThe short-term application of topical corticosteroids and maintaining the results with a less potent agent can prove to be an effective option for treating patients with intertriginous psoriasis (IP) as per a recently concluded study by Alexander Kreuter, M.D, from Ruhr University of Bochum, Germany and colleagues.

From Bio-Medicine.Org:

In this study, Alexander Kreuter, M.D, from Ruhr University of Bochum, Germany, and colleagues conducted a randomized controlled trial that compared 1 percent pimecrolimus (a new anti-inflammatory drug), 0.005 percent calcipotriol, 0.1 percent betamethasone and the vehicle (a similarly appearing cream with no active drug) in the treatment of IP with a four-week treatment period and a six-week follow-up without therapy. A total of 80 adult patients with the clinical diagnosis of IP were included, 20 patients in each of the four treatment groups.

“After four weeks of treatment, the three active compounds and the vehicle resulted in a significant decrease in mean (average) M-PASI score [Modified Psoriasis Area and Severity Index] (86.4 percent for 0.1 percent betamethasone, 62.4 percent for 0.005 percent calcipotriol, 39.7 percent for 1 percent pimecrolimus and 21.1 percent for vehicle),” the researchers found. “The 0.1 percent betamethasone was significantly more effective than 1 percent pimecrolimus during the study period.”

The study findings are expected to provide much-awaited relief to IP patients on a worldwide basis who often struggle with symptoms such as soreness and irritation from sweating.

This study was quick to crush down the myth that corticosteroids may bring some side effects with them in the long run. It showed that a short-term application of corticosteroids for acute diseases followed by maintenance treatment options with less potent agents is just the right way for treating ailments such as intertriginous psoriasis (IP).


Comments